Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
1.400
+0.030 (2.19%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Purple Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 5.57 | 8.72 | 7.4 | 14.49 | 15.03 | 10.89 |
Short-Term Investments | 0.86 | 0.86 | 1.12 | 0.92 | 17.08 | 36.31 |
Cash & Short-Term Investments | 6.43 | 9.57 | 8.52 | 15.41 | 32.11 | 47.2 |
Cash Growth | -9.33% | 12.32% | -44.69% | -52.01% | -31.96% | -18.35% |
Other Current Assets | 0.35 | 0.29 | 0.38 | 0.38 | 1.14 | 1.27 |
Total Current Assets | 6.78 | 9.87 | 8.91 | 15.79 | 33.26 | 48.47 |
Net Property, Plant & Equipment | 0.28 | 0.35 | 0.29 | 0.47 | 0.68 | 0.9 |
Other Intangible Assets | 7.36 | 7.36 | 27.84 | 28.04 | 20.68 | 20.48 |
Long-Term Investments | - | - | - | - | - | 0.19 |
Other Long-Term Assets | - | - | - | - | - | 0.16 |
Total Assets | 14.42 | 17.57 | 37.04 | 44.3 | 54.62 | 70.2 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.84 | 2.07 | 1.46 | 3.53 | 2.13 | 1.47 |
Accrued Expenses | 1.67 | 1.37 | 1.2 | 3.46 | 4.73 | 2.58 |
Current Portion of Leases | 0.18 | 0.24 | 0.18 | 0.19 | 0.19 | 0.2 |
Other Current Liabilities | 1.9 | 4.07 | 1.15 | 2.52 | - | - |
Total Current Liabilities | 4.59 | 7.75 | 3.99 | 9.7 | 7.06 | 4.25 |
Long-Term Leases | - | - | - | 0.16 | 0.32 | 0.55 |
Other Long-Term Liabilities | 0.16 | 0.16 | 0.14 | 0.14 | 0.15 | 0.29 |
Total Long-Term Liabilities | 0.16 | 0.16 | 0.14 | 0.3 | 0.47 | 0.84 |
Total Liabilities | 4.75 | 7.91 | 4.13 | 10.01 | 7.52 | 5.09 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-in Capital | 180.89 | 180.79 | 177.55 | 171.64 | 164.49 | 160.73 |
Accumulated Other Comprehensive Income | - | - | - | 0.02 | -0.01 | - |
Retained Earnings | -171.17 | -171.08 | -144.69 | -137.45 | -117.57 | -95.91 |
Total Common Shareholders' Equity | 9.72 | 9.71 | 32.86 | 34.21 | 46.91 | 64.83 |
Minority Interest | -0.06 | -0.06 | 0.05 | 0.09 | 0.19 | 0.28 |
Shareholders' Equity | 9.66 | 9.66 | 32.91 | 34.3 | 47.1 | 65.11 |
Total Liabilities & Equity | 14.42 | 17.57 | 37.04 | 44.3 | 54.62 | 70.2 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.18 | 0.24 | 0.18 | 0.35 | 0.52 | 0.75 |
Net Cash (Debt) | 6.24 | 9.33 | 8.34 | 15.06 | 31.6 | 46.45 |
Net Cash Growth | -10.19% | 11.86% | -44.62% | -52.34% | -31.98% | -18.38% |
Net Cash Per Share | 8.76 | 19.43 | 50.87 | 136.09 | 34.95 | 4.04 |
Book Value | 9.72 | 9.71 | 32.86 | 34.21 | 46.91 | 64.83 |
Book Value Per Share | 13.64 | 20.24 | 200.42 | 309.10 | 51.89 | 5.64 |
Tangible Book Value | 2.36 | 2.35 | 5.02 | 6.16 | 26.23 | 44.35 |
Tangible Book Value Per Share | 3.31 | 4.90 | 30.61 | 55.69 | 29.01 | 3.86 |